Chronic Idiopathic Constipation Market – Global Industry Analysis and forecast (2023- 2029)

Chronic Idiopathic Constipation Market is expected to reach US$ 20.97 Bn. at a CAGR of 7 % during the forecast period 2029. Chronic Idiopathic Constipation i.e. CIC is called as the chronic existence of these symptoms (constipation). It is known as idiopathic because the cause of this type of constipation is unknown and it is not initiated by an underlying disease or medication. In the U.S. as many as 35 Mn. adults may suffer from CIC. The numbers may be greater as all patients do not seek medical help. Studies have shown that only approximately 12% with the disorder seek medical help. Now, yet, 40% of patients with chronic idiopathic constipation are under medicine. It is slightly further common in women around 56% and adults above the age of 35 years around 84%. The MMR report analyzes various factors which have been driving the global CIC market in the past. The report also showcases the opportunities available in the chronic idiopathic constipation market which may act as a future driver for the global market. Such as growing clinical trials and approval of drug applicants by pharmaceutical players to fulfill unmet medical needs of the CIC treatment is a major factor fueling the market growth over 2023-2029. On the flip side, a restricted operating revenue opportunity for R&D of targeted therapies by various pharmaceuticals is acting as a challenging factor for the growth of global chronic idiopathic constipation market.Chronic Idiopathic Constipation MarketTo know about the Research Methodology :- Request Free Sample Report The report covers the segments in the chronic idiopathic constipation market such as route of administration, drug class, and distribution channel. Based on drug class, the laxatives segment is expected to grow at the highest xx% CAGR during the forecast period. Laxatives can aid with softening stool and improving the regularity of bowel actions. Fiber supplements have a related effect. By route of administration, the oral segment dominated the market, with market size of US$ xx Mn. in 2022 and to reach US$ xx Mn. by 2029, with a CAGR of xx.05%. As patients prefer taking oral drugs as they are invasive, convenient, and need no different training to take drugs. The research study includes the profiles of leading companies operating in the market globally. Such as, in 2018, Mallinckrodt Company, a worldwide specialty pharmaceutical company, announced the acquisition of Sucampo Pharmaceuticals Company, a biopharmaceutical company. The acquisition assets contain its FDA accepted blockbuster drug Amitiza i.e. lubiprostone for the treatment of CIC in adults, IBS-C (irritable bowel syndrome with constipation). North America is expected to continue to hold the largest xx% share in the chronic idiopathic constipation market. Higher awareness amongst physicians and patient population considerably contribute the CIS market growth in the USA. Initial commercialization of the drug in the United States also adds up to the high demand of the drug in this market. However, a gradual overview of Linaclotide in other emerging markets will facilitate market growth in the APAC market. India, China, Japan, and Australia are the major countrywide markets that are likely to give the highest revenue contributions to the APAC chronic idiopathic constipation market. The objective of the report is to present a comprehensive analysis of the global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding global market dynamics, structure by analyzing the market segments and projects the global market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.

Chronic Idiopathic Constipation Market Scope: Inquire before buying

Chronic Idiopathic Constipation Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 13.05 Bn.
Forecast Period 2023 to 2029 CAGR: 7% Market Size in 2029: US $ 20.97 Bn.
Segments Covered: by Drug Class Emollients Laxatives Bulk-forming Agents Osmotic Agents Other Drug Class
by Distribution Channel Oral Parental
by Application Hospital Pharmacies Retail Pharmacies Online Pharmacies

by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Chronic Idiopathic Constipation Market Key Players :

1. Actavis 2. Chugai Pharmaceutical 3. Ferring International Center S.A. 4. Synergy Pharmaceuticals 5. Pfizer 6. GlaxoSmithKline 7. Roche Holding AG 8. Sanofi 9. Bayer AG 10. Salix Pharmaceuticals Ltd 11. Sucampo Pharmaceuticals Inc 12. Ironwood Pharmaceuticals 13. Progenics Pharmaceuticals 14. Merck Sharp & Dohme 15. Theravance Biopharma Inc Frequently Asked Questions: 1. Which region has the largest share in Global Chronic Idiopathic Constipation Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Chronic Idiopathic Constipation Market? Ans: The Global Chronic Idiopathic Constipation Market is growing at a CAGR of 7% during forecasting period 2023-2029. 3. What is scope of the Global Chronic Idiopathic Constipation market report? Ans: Global Chronic Idiopathic Constipation Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Chronic Idiopathic Constipation market? Ans: The important key players in the Global Chronic Idiopathic Constipation Market are – Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, 5. What is the study period of this market? Ans: The Global Chronic Idiopathic Constipation Market is studied from 2022 to 2029.
Global Chronic Idiopathic Constipation Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Chronic Idiopathic Constipation Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Chronic Idiopathic Constipation Market Analysis and Forecast 6.1. Chronic Idiopathic Constipation Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Chronic Idiopathic Constipation Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 7.4. Chronic Idiopathic Constipation Market Size (US$ Bn) Forecast, By Drug Class 7.5. Chronic Idiopathic Constipation Market Analysis, By Drug Class 7.6. Chronic Idiopathic Constipation Market Attractiveness Analysis, By Drug Class 8. Global Chronic Idiopathic Constipation Market Analysis and Forecast, By Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 8.4. Chronic Idiopathic Constipation Market Size (US$ Bn) Forecast, By Route of Administration 8.5. Chronic Idiopathic Constipation Market Analysis, By Route of Administration 8.6. Chronic Idiopathic Constipation Market Attractiveness Analysis, By Route of Administration 9. Global Chronic Idiopathic Constipation Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 9.4. Chronic Idiopathic Constipation Market Size (US$ Bn) Forecast, By Distribution Channel 9.5. Chronic Idiopathic Constipation Market Analysis, By Distribution Channel 9.6. Chronic Idiopathic Constipation Market Attractiveness Analysis, By Distribution Channel 10. Global Chronic Idiopathic Constipation Market Analysis, by Region 10.1. Chronic Idiopathic Constipation Market Value Share Analysis, by Region 10.2. Chronic Idiopathic Constipation Market Size (US$ Bn) Forecast, by Region 10.3. Chronic Idiopathic Constipation Market Attractiveness Analysis, by Region 11. North America Chronic Idiopathic Constipation Market Analysis 11.1. Key Findings 11.2. North America Chronic Idiopathic Constipation Market Overview 11.3. North America Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 11.4. North America Chronic Idiopathic Constipation Market Forecast, By Drug Class 11.4.1. Emollients 11.4.2. Laxatives 11.4.3. Bulk-forming Agents 11.4.4. Osmotic Agents 11.4.5. Other Drug Class 11.5. North America Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 11.6. North America Chronic Idiopathic Constipation Market Forecast, By Route of Administration 11.6.1. Oral 11.6.2. Parental 11.7. North America Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 11.8. North America Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America Chronic Idiopathic Constipation Market Value Share Analysis, by Country 11.10. North America Chronic Idiopathic Constipation Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Chronic Idiopathic Constipation Market Analysis, by Country 11.12. U.S. Chronic Idiopathic Constipation Market Forecast, By Drug Class 11.12.1. Emollients 11.12.2. Laxatives 11.12.3. Bulk-forming Agents 11.12.4. Osmotic Agents 11.12.5. Other Drug Class 11.13. U.S. Chronic Idiopathic Constipation Market Forecast, By Route of Administration 11.13.1. Oral 11.13.2. Parental 11.14. U.S. Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada Chronic Idiopathic Constipation Market Forecast, By Drug Class 11.15.1. Emollients 11.15.2. Laxatives 11.15.3. Bulk-forming Agents 11.15.4. Osmotic Agents 11.15.5. Other Drug Class 11.16. Canada Chronic Idiopathic Constipation Market Forecast, By Route of Administration 11.16.1. Oral 11.16.2. Parental 11.17. Canada Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. North America Chronic Idiopathic Constipation Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Route of Administration 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Chronic Idiopathic Constipation Market Analysis 12.1. Key Findings 12.2. Europe Chronic Idiopathic Constipation Market Overview 12.3. Europe Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 12.4. Europe Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.4.1. Emollients 12.4.2. Laxatives 12.4.3. Bulk-forming Agents 12.4.4. Osmotic Agents 12.4.5. Other Drug Class 12.5. Europe Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 12.6. Europe Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.6.1. Oral 12.6.2. Parental 12.7. Europe Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 12.8. Europe Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe Chronic Idiopathic Constipation Market Value Share Analysis, by Country 12.10. Europe Chronic Idiopathic Constipation Market Forecast, by Country 12.10.1. Germany 12.10.2. UK 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Russia 12.11. Europe Chronic Idiopathic Constipation Market Analysis, by Country 12.12. Germany Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.12.1. Emollients 12.12.2. Laxatives 12.12.3. Bulk-forming Agents 12.12.4. Osmotic Agents 12.12.5. Other Drug Class 12.13. Germany Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.13.1. Oral 12.13.2. Parental 12.14. Germany Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Online Pharmacies 12.15. U.K. Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.15.1. Emollients 12.15.2. Laxatives 12.15.3. Bulk-forming Agents 12.15.4. Osmotic Agents 12.15.5. Other Drug Class 12.15.6. Satiety drugs 12.16. U.K. Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.16.1. Oral 12.16.2. Parental 12.17. U.K. Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. France Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.18.1. Emollients 12.18.2. Laxatives 12.18.3. Bulk-forming Agents 12.18.4. Osmotic Agents 12.18.5. Other Drug Class 12.19. France Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.19.1. Oral 12.19.2. Parental 12.20. France Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Online Pharmacies 12.21. Italy Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.21.1. Emollients 12.21.2. Laxatives 12.21.3. Bulk-forming Agents 12.21.4. Osmotic Agents 12.21.5. Other Drug Class 12.22. Italy Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.22.1. Oral 12.22.2. Parental 12.23. Italy Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Spain Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.24.1. Emollients 12.24.2. Laxatives 12.24.3. Bulk-forming Agents 12.24.4. Osmotic Agents 12.24.5. Other Drug Class 12.25. Spain Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.25.1. Oral 12.25.2. Parental 12.26. Spain Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Online Pharmacies 12.27. Norway Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.27.1. Emollients 12.27.2. Laxatives 12.27.3. Bulk-forming Agents 12.27.4. Osmotic Agents 12.27.5. Other Drug Class 12.28. Norway Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.28.1. Oral 12.28.2. Parental 12.29. Norway Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Online Pharmacies 12.30. Russia Chronic Idiopathic Constipation Market Forecast, By Drug Class 12.30.1. Emollients 12.30.2. Laxatives 12.30.3. Bulk-forming Agents 12.30.4. Osmotic Agents 12.30.5. Other Drug Class 12.31. Russia Chronic Idiopathic Constipation Market Forecast, By Route of Administration 12.31.1. Oral 12.31.2. Parental 12.32. Russia Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 12.32.1. Hospital Pharmacies 12.32.2. Retail Pharmacies 12.32.3. Online Pharmacies 12.33. Europe Chronic Idiopathic Constipation Market Attractiveness Analysis 12.33.1. By Drug Class 12.33.2. By Route of Administration 12.33.3. By Distribution Channel 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Developments 13. Asia Pacific Chronic Idiopathic Constipation Market Analysis 13.1. Key Findings 13.2. Asia Pacific Chronic Idiopathic Constipation Market Overview 13.3. Asia Pacific Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.4.1. Emollients 13.4.2. Laxatives 13.4.3. Bulk-forming Agents 13.4.4. Osmotic Agents 13.4.5. Other Drug Class 13.5. Asia Pacific Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 13.6. Asia Pacific Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.6.1. Oral 13.6.2. Parental 13.7. Asia Pacific Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific Chronic Idiopathic Constipation Market Value Share Analysis, by Country 13.10. Asia Pacific Chronic Idiopathic Constipation Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.10.8. Vietnam 13.11. Asia Pacific Chronic Idiopathic Constipation Market Analysis, by Country 13.12. China Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.12.1. Emollients 13.12.2. Laxatives 13.12.3. Bulk-forming Agents 13.12.4. Osmotic Agents 13.12.5. Other Drug Class 13.13. China Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.13.1. Oral 13.13.2. Parental 13.14. China Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.15.1. Emollients 13.15.2. Laxatives 13.15.3. Bulk-forming Agents 13.15.4. Osmotic Agents 13.15.5. Other Drug Class 13.16. India Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.16.1. Oral 13.16.2. Parental 13.17. India Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.18.1. Emollients 13.18.2. Laxatives 13.18.3. Bulk-forming Agents 13.18.4. Osmotic Agents 13.18.5. Other Drug Class 13.19. Japan Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.19.1. Oral 13.19.2. Parental 13.20. Japan Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. South Korea Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.21.1. Emollients 13.21.2. Laxatives 13.21.3. Bulk-forming Agents 13.21.4. Osmotic Agents 13.21.5. Other Drug Class 13.22. South Korea Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.22.1. Oral 13.22.2. Parental 13.23. South Korea Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Australia Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.24.1. Emollients 13.24.2. Laxatives 13.24.3. Bulk-forming Agents 13.24.4. Osmotic Agents 13.24.5. Other Drug Class 13.25. Australia Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.25.1. Oral 13.25.2. Parental 13.26. Australia Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. Malaysia Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.27.1. Emollients 13.27.2. Laxatives 13.27.3. Bulk-forming Agents 13.27.4. Osmotic Agents 13.27.5. Other Drug Class 13.28. Malaysia Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.28.1. Oral 13.28.2. Parental 13.29. Malaysia Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.29.1. Hospital Pharmacies 13.29.2. Retail Pharmacies 13.29.3. Online Pharmacies 13.30. Indonesia Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.30.1. Emollients 13.30.2. Laxatives 13.30.3. Bulk-forming Agents 13.30.4. Osmotic Agents 13.30.5. Other Drug Class 13.31. Indonesia Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.31.1. Oral 13.31.2. Parental 13.32. Indonesia Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.32.1. Hospital Pharmacies 13.32.2. Retail Pharmacies 13.32.3. Online Pharmacies 13.33. Vietnam Chronic Idiopathic Constipation Market Forecast, By Drug Class 13.33.1. Emollients 13.33.2. Laxatives 13.33.3. Bulk-forming Agents 13.33.4. Osmotic Agents 13.33.5. Other Drug Class 13.34. Vietnam Chronic Idiopathic Constipation Market Forecast, By Route of Administration 13.34.1. Oral 13.34.2. Parental 13.35. Vietnam Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 13.35.1. Hospital Pharmacies 13.35.2. Retail Pharmacies 13.35.3. Online Pharmacies 13.36. Asia Pacific Chronic Idiopathic Constipation Market Attractiveness Analysis 13.36.1. By Drug Class 13.36.2. By Route of Administration 13.36.3. By Distribution Channel 13.37. PEST Analysis 13.38. Key Trends 13.39. Key Developments 14. Middle East & Africa Chronic Idiopathic Constipation Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Chronic Idiopathic Constipation Market Overview 14.3. Middle East & Africa Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Chronic Idiopathic Constipation Market Forecast, By Drug Class 14.4.1. Emollients 14.4.2. Laxatives 14.4.3. Bulk-forming Agents 14.4.4. Osmotic Agents 14.4.5. Other Drug Class 14.5. Middle East & Africa Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 14.6. Middle East & Africa Chronic Idiopathic Constipation Market Forecast, By Route of Administration 14.6.1. Oral 14.6.2. Parental 14.7. Middle East & Africa Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa Chronic Idiopathic Constipation Market Value Share Analysis, by Country 14.10. Middle East & Africa Chronic Idiopathic Constipation Market Forecast, by Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.11. Middle East & Africa Chronic Idiopathic Constipation Market Analysis, by Country 14.12. GCC Chronic Idiopathic Constipation Market Forecast, By Drug Class 14.12.1. Emollients 14.12.2. Laxatives 14.12.3. Bulk-forming Agents 14.12.4. Osmotic Agents 14.12.5. Other Drug Class 14.13. GCC Chronic Idiopathic Constipation Market Forecast, By Route of Administration 14.13.1. Oral 14.13.2. Parental 14.14. GCC Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa Chronic Idiopathic Constipation Market Forecast, By Drug Class 14.15.1. Emollients 14.15.2. Laxatives 14.15.3. Bulk-forming Agents 14.15.4. Osmotic Agents 14.15.5. Other Drug Class 14.16. South Africa Chronic Idiopathic Constipation Market Forecast, By Route of Administration 14.16.1. Oral 14.16.2. Parental 14.17. South Africa Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Nigeria Chronic Idiopathic Constipation Market Forecast, By Drug Class 14.18.1. Emollients 14.18.2. Laxatives 14.18.3. Bulk-forming Agents 14.18.4. Osmotic Agents 14.18.5. Other Drug Class 14.19. Nigeria Chronic Idiopathic Constipation Market Forecast, By Route of Administration 14.19.1. Oral 14.19.2. Parental 14.20. Nigeria Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Egypt Chronic Idiopathic Constipation Market Forecast, By Drug Class 14.21.1. Emollients 14.21.2. Laxatives 14.21.3. Bulk-forming Agents 14.21.4. Osmotic Agents 14.21.5. Other Drug Class 14.22. Egypt Chronic Idiopathic Constipation Market Forecast, By Route of Administration 14.22.1. Oral 14.22.2. Parental 14.23. Egypt Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 14.23.1. Hospital Pharmacies 14.23.2. Retail Pharmacies 14.23.3. Online Pharmacies 14.24. Middle East & Africa Chronic Idiopathic Constipation Market Attractiveness Analysis 14.24.1. By Drug Class 14.24.2. By Route of Administration 14.24.3. By Distribution Channel 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. South America Chronic Idiopathic Constipation Market Analysis 15.1. Key Findings 15.2. South America Chronic Idiopathic Constipation Market Overview 15.3. South America Chronic Idiopathic Constipation Market Value Share Analysis, By Drug Class 15.4. South America Chronic Idiopathic Constipation Market Forecast, By Drug Class 15.4.1. Emollients 15.4.2. Laxatives 15.4.3. Bulk-forming Agents 15.4.4. Osmotic Agents 15.4.5. Other Drug Class 15.5. South America Chronic Idiopathic Constipation Market Value Share Analysis, By Route of Administration 15.6. South America Chronic Idiopathic Constipation Market Forecast, By Route of Administration 15.6.1. Oral 15.6.2. Parental 15.7. South America Chronic Idiopathic Constipation Market Value Share Analysis, By Distribution Channel 15.8. South America Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America Chronic Idiopathic Constipation Market Value Share Analysis, by Country 15.10. South America Chronic Idiopathic Constipation Market Forecast, by Country 15.10.1. Mexico 15.10.2. Brazil 15.10.3. Argentina 15.11. South America Chronic Idiopathic Constipation Market Analysis, by Country 15.12. Brazil Chronic Idiopathic Constipation Market Forecast, By Drug Class 15.12.1. Emollients 15.12.2. Laxatives 15.12.3. Bulk-forming Agents 15.12.4. Osmotic Agents 15.12.5. Endoscopic Procedures 15.13. Brazil Chronic Idiopathic Constipation Market Forecast, By Route of Administration 15.13.1. Oral 15.13.2. Parental 15.14. Brazil Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Mexico Chronic Idiopathic Constipation Market Forecast, By Drug Class 15.15.1. Emollients 15.15.2. Laxatives 15.15.3. Bulk-forming Agents 15.15.4. Osmotic Agents 15.15.5. Other Drug Class 15.16. Mexico Chronic Idiopathic Constipation Market Forecast, By Route of Administration 15.16.1. Oral 15.16.2. Parental 15.17. Mexico Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Argentina Chronic Idiopathic Constipation Market Forecast, By Drug Class 15.18.1. Emollients 15.18.2. Laxatives 15.18.3. Bulk-forming Agents 15.18.4. Osmotic Agents 15.18.5. Other Drug Class 15.19. Argentina Chronic Idiopathic Constipation Market Forecast, By Route of Administration 15.19.1. Oral 15.19.2. Parental 15.20. Argentina Chronic Idiopathic Constipation Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. South America Chronic Idiopathic Constipation Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Route of Administration 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Actavis 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Chugai Pharmaceutical 16.3.3. Ferring International Center S.A. 16.3.4. Synergy Pharmaceuticals 16.3.5. Pfizer 16.3.6. GlaxoSmithKline 16.3.7. Roche Holding AG 16.3.8. Sanofi 16.3.9. Bayer AG 16.3.10. Salix Pharmaceuticals Ltd 16.3.11. Sucampo Pharmaceuticals Inc 16.3.12. Ironwood Pharmaceuticals 16.3.13. Progenics Pharmaceuticals 16.3.14. Merck Sharp & Dohme 16.3.15. Theravance Biopharma Inc 17. Primary Key Insights
  • INQUIRE BEFORE BUYING